KetoSwiss develops “brain fuels” as nutraceuticals (supplements) and pharmaceuticals for the therapy of migraine (“MigraKet”), which are productive and close to the root cause of migraine without adding intolerable side effects. Its lead product’s active substance is an endogenous metabolite, a ketone body, which can be used by the brain as an alternative fuel to …

Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting …

EG 427 is a biotechnology company leading the development of pinpoint DNA medicine solutions. It has developed a non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform which delivers, with pinpoint precision, highly selective, durable expression of disease-modifying transgenes. The company leverages the technology to design new treatments for peripheral nervous system disorders and …

Tenpoint Therapeutics is a biotechnology company advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases. It brings together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. Tenpoint aims to address the ultimate cause of vision loss by …

Camena Bioscience is a synthetic biology company with novel DNA synthesis technology. Built on over seven years of innovation and with deep insight into the challenges faced in the pharmaceutical and biotechnology industries, their pioneering platform gSynth is rewriting the possibilities of DNA synthesis by unlocking access to genes with unparalleled accuracy and speed. Over …

Proxygen develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. It is focused on particular small molecules called “molecular glue degraders,” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of …

Orakl leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With its platform, the company partners with oncology players to identify relevant targets and deliver new drugs, faster.

Turbine was founded to overcome the limitations of existing methods in identifying oncology treatments that truly benefit the patients who receive them by combining molecular biology and artificial intelligence. The company has developed and validated the Simulated Cell, a proprietary and cutting-edge platform that runs billions of simulations prior to ever initiating preclinical development guiding …

Omniscope has developed an AI-enabled platform to perform high-precision immune profiling, which is the process of understanding why people respond differently to viruses, to inform research, diagnostics, and therapeutic development. The company’s OS-T technology allows mapping of a complete T cell response, up to 1 million T cells per clinical sample. Its other offering, OS-IP, …

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules, including cytokines that can stimulate or suppress T cells. The company’s patented TILT technology, which can be delivered locally and systemically, modifies the tumor microenvironment and eliminates its ability to suppress immune responses to cancer, thereby …

A spin-off from from Fraunhofer Institute for Immune Pathology and Immune Tolerance, Phialogics is a preclinical biotech company specializing in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed …

Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. The company is building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each …

DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/β-catenin signaling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development. In addition to its headquarters in Marseille, …

A spin-out from Newcastle University, NunaBio has developed a platform that enables the synthesis of whole genes and DNA fragments of unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the synthetic biology industry. Its technology has broad applications across multiple areas of life sciences, including gene therapy, T cell …

Novai is a cutting-edge biotech company developing solutions for the detection and treatment of retinal diseases. At the heart of Novai’s technology is DARC (Detection of Apoptosing in Retinal Cells), a revolutionary method for detecting early signs of apoptosis (cell death) in the retina. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm …

A spin-out from Newcastle University, AMLo Biosciences is developing predictive tests for cancers with unmet needs. Its first product is an immunohistochemical test for non-ulcerated, cutaneous melanomas, which can accurately identify those tumors at low risk of recurrence/spread, reducing patient anxiety associated with cancer.

Enthera is a biotech company building a pipeline of first-in-class biologics for several underserved autoimmune conditions, with a focus on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). It aims to develop disease-modifying treatments by preserving and re-establishing cell and organ function to revert the outcome of these conditions. Enthera’s therapeutics are founded on …

A spin-out from The University of Copenhagen and Rigshospitalet, Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs). The company’s drugs are directed at a target receptor uPARAP, which allows targeted therapy in several cancer forms where expression of the target has been found to be highly unregulated, including …

Founded through a collaboration between argenx and the University of Torino, Italy – Agomab is translating deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, it is …

Formerly called ProteoDesign, SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Its platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. In this novel approach, engineered inteins catalyze highly efficient protein …